Xenon PharmaceuticalsXENE
XENE
About: Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Employees: 327
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
114% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $6.93M
8% more funds holding in top 10
Funds holding in top 10: 13 [Q4 2024] → 14 (+1) [Q1 2025]
0.18% more ownership
Funds ownership: 100.06% [Q4 2024] → 100.25% (+0.18%) [Q1 2025]
1% less funds holding
Funds holding: 208 [Q4 2024] → 206 (-2) [Q1 2025]
8% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 73
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
14% less capital invested
Capital invested by funds: $2.99B [Q4 2024] → $2.58B (-$414M) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$47
43%
upside
Avg. target
$53
62%
upside
High target
$55
68%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Evercore ISI Group Cory Kasimov | 68%upside $55 | Outperform Initiated | 14 May 2025 |
Wells Fargo Mohit Bansal | 43%upside $47 | Overweight Maintained | 13 May 2025 |
RBC Capital Brian Abrahams | 68%upside $55 | Outperform Maintained | 13 May 2025 |
HC Wainwright & Co. Douglas Tsao | 62%upside $53 | Buy Reiterated | 13 May 2025 |
Needham Serge Belanger | 68%upside $55 | Buy Maintained | 13 May 2025 |
Financial journalist opinion
Based on 3 articles about XENE published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
1 week ago
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025.
Neutral
GlobeNewsWire
2 weeks ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 53,550 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 29, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum
30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI 30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI
Neutral
GlobeNewsWire
1 month ago
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025.
Positive
Zacks Investment Research
1 month ago
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Neutral
Seeking Alpha
1 month ago
Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 AM ET Corporate Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Tessa Romero - JPMorgan Brian Abrahams - RBC Capital Markets Brian Skorney - Baird Myles Minter - William Blair Dylan Shindler - Wedbush Daniel Ni - Goldman Sachs Andrew Tsai - Jefferies Joseph Thome - TD Cowen Operator Thank you for standing by. My name is Carly, and I will be your conference operator today.
Neutral
GlobeNewsWire
1 month ago
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026
Neutral
GlobeNewsWire
1 month ago
Xenon to Report Q1 2025 Financial Results on May 12, 2025
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Charts implemented using Lightweight Charts™